Exam (elaborations)
ATI PHARM MADE EASY 4.0 MUSCULOSKELETAL SYSTEM QUESTIONS AND ANSWERS
ATI PHARM MADE EASY 4.0 MUSCULOSKELETAL SYSTEM QUESTIONS AND ANSWERS
[Show more]
Preview 2 out of 12 pages
Uploaded on
November 1, 2024
Number of pages
12
Written in
2024/2025
Type
Exam (elaborations)
Contains
Unknown
Institution
ATI Pharm
Course
ATI Pharm
$14.99
Also available in package deal from $49.16
100% satisfaction guarantee
Immediately available after payment
Both online and in PDF
No strings attached
Also available in package deal (1)
1. Exam (elaborations) - Pharmacology made easy 4.0 the musculoskeletal system questions and answers
2. Exam (elaborations) - Ati pharm made easy 4.0 musculoskeletal system questions and answers
3. Exam (elaborations) - Ati pharm made easy 4.0 musculoskeletal system questions and answers
4. Exam (elaborations) - Ati pharm made easy 4.0 musculoskeletal system questions and answers
5. Exam (elaborations) - Pharm made easy 4.0 hematologic system
Show more
ATI PHARMACOLOGY MADE EASY 4.0 ~
THE NEUROLOGICAL SYSTEM (PART 1)
A6nurse6is6teaching6a6client6who6has6Alzheimer's6disease6and6their6caregiver6about6mem
antine.6Which6of6the6following6instructions6should6the6nurse6include?
A.6Increase6fluid6intake6to6improve6renal6excretion.
B.6Report6memory6loss6or6confusion.
C.6Watch6for6signs6of6liver6impairment,6such6as6jaundice6and6abdominal6pain.
D.6Avoid6taking6over-the-counter6antacids.6-6ans--D.6Avoid6taking6over-the-
counter6antacids.
Rationale:
A.6It6is6not6necessary6to6increase6fluids.6Memantine6is6essentially6unchanged6when6it6is6
excreted6in6the6urine.6Therefore,6it6is6not6necessary6to6increase6fluids6because6fluid6intak
e6does6not6affect6this6process.
B.6Clients6who6have6Alzheimer's6disease6already6have6and6will6continue6to6have6memor
y6loss6and6confusion.6The6drug6can6help6slow6the6progressive6decline,6but6will6not6elimin
ate6the6disease's6manifestations.
C.6Memantine6should6not6result6in6liver6impairment,6although6it6should6be6used6cautiousl
y6with6clients6who6have6severe6liver6impairment.
D.6Antacids6that6contain6sodium6bicarbonate6increase6urine6alkalinity6and6can6decrease6
drug6excretion,6ultimately6leading6to6toxicity.
A6nurse6is6caring6for6a6client6who6has6a6new6prescription6for6pramipexole6to6treat6Parkins
on's6disease.6The6nurse6should6recognize6that6which6of6the6following6laboratory6tests6re
quires6monitoring?
A.6C-reactive6protein
B.6Creatinine6clearance
C.6Thyroid6function
D.6CBC6-6ans--B.6Creatinine6clearance
Rationale:
A.6Pramipexole,6a6direct-acting6dopamine6receptor6agonist,6is6unlikely6to6alter6C-
reactive6protein.6Pravastatin6is6a6drug6that6alters6C-
reactive6protein6in6a6beneficial6way6by6helping6to6lower6the6risk6of6heart6disease.
, B.6Pramipexole,6a6direct-
acting6dopamine6receptor6agonist,6should6be6used6with6caution6for6clients6who6have6ren
al6disease.6Therefore,6the6nurse6should6monitor6the6client's6renal6function.
C.6Pramipexole,6a6direct-
acting6dopamine6receptor6agonist,6is6unlikely6to6alter6thyroid6function.6Amiodarone6is6a6d
rug6that6can6alter6thyroid6function.
D.6Pramipexole,6a6direct-
acting6dopamine6receptor6agonist,6is6unlikely6to6alter6CBCs.6Interferon6beta-
1b,6an6immunomodulator,6can6cause6myelosuppression6and6warrants6monitoring6of6CB
Cs6periodically.
A6nurse6is6caring6for6a6client6who6has6a6new6prescription6for6dantrolene6to6treat6skeletal6
muscle6spasms.6The6nurse6should6instruct6the6client6to6report6which6of6the6following6adv
erse6effects?
A.6Slow6heart6rate
B.6Cough
C.6Diarrhea
D.6Hearing6loss6-6ans--C.6Diarrhea
Rationale:
A.6Dantrolene6is6more6likely6to6cause6tachycardia6than6bradycardia.
B.6Dantrolene6is6unlikely6to6cause6a6cough,6but6it6can6cause6difficulty6swallowing.
C.6Prolonged6diarrhea6can6cause6dehydration6and6other6serious6effects.6Diarrhea,6naus
ea,6and6vomiting6are6adverse6effects6of6dantrolene.6The6client6should6report6these6effect
s6so6the6nurse6can6monitor6fluid6balance6and6intervene6accordingly.
D.6Dantrolene6can6cause6blurred6vision,6but6it6is6unlikely6to6cause6hearing6loss.
A6nurse6is6caring6for6a6client6who6has6a6new6prescription6for6valproic6acid6to6treat6a6seizu
re6disorder.6The6nurse6should6instruct6the6client6to6monitor6for6which6of6the6following6adv
erse6effects?
A.6Hirsutism
B.6Depression
C.6Jaundice
D.6Gum6irritation6-6ans--C.6Jaundice
Rationale:
A.6Valproic6acid6is6unlikely6to6cause6hirsutism,6or6excessive6hair6growth,6but6it6can6cause
6transient6hair6loss.
B.6Valproic6acid6is6unlikely6to6cause6depression,6but6it6can6cause6aggression.
C.6Valproic6acid6can6cause6hepatic6toxicity,6characterized6by6jaundice,6abdominal6pain,6
and6nausea.6Clients6taking6the6drug6should6report6these6manifestations,6and6the6nurse6s
hould6monitor6liver6function6studies6prior6to6treatment6and6periodically6during6therapy.
D.6Valproic6acid6is6unlikely6to6cause6gum6irritation.6Phenytoin6can6cause6gingival6hyperpl
asia.